Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Current progress in pharmacogenetics and individualized immunosuppressive drug dosing in organ transplantation.

Current opinion in molecular therapeutics - 1 Jun 2010

Ware Nicholas, MacPhee Iain A M

Abstract excerpt

The immunosuppressive drugs used in organ transplantation typically have a narrow therapeutic index, with wide variation in the blood concentration achieved from a given dose observed between individuals. This issue has been addressed through the use of therapeutic drug monitoring (TDM), but it may take 5 to 7 days to reach target blood concentrations using this approach. This timeline is not conducive to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytochrome P-450 CYP3A
Share to Drug Monitoring
Share to Graft Rejection

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Half-Life

Share to Immunosuppressive Agents

Share to Pharmacogenetics

Share to Sirolimus

Share to Tacrolimus

Source

Identifiers

PMID: 20521216

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Current progress in pharmacogenetics and individualized immunosuppressive drug dosing in organ transplantation.PMID 20521216Read ↗

Current progress of tacrolimus dosing in solid organ transplant recipients: Pharmacogenetic considerations.Semantic proximity Read ↗

Pharmacogenetic biomarkers: cytochrome P450 3A5.Semantic proximity Read ↗

Use of pharmacogenetics to optimize immunosuppressive therapy.Semantic proximity Read ↗

Dosing tacrolimus based on CYP3A5 genotype: will it improve clinical outcome?Semantic proximity Read ↗

A pharmacogenetic strategy for immunosuppression based on the CYP3A5 genotype.Semantic proximity Read ↗

Pharmacogenetics in solid organ transplantation: present knowledge and future perspectives.Semantic proximity Read ↗

Pharmacogenetics in solid organ transplantation: current status and future directions.Semantic proximity Read ↗

Pharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patients.Semantic proximity Read ↗

The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation.Semantic proximity Read ↗

[Pharmacogenetics of tacrolimus: from bench to bedside?].Semantic proximity Read ↗

Recent advances in precision medicine for individualized immunosuppression.Semantic proximity Read ↗

Use of Pharmacogenetics to Optimize Immunosuppressant Therapy in Kidney-Transplanted PatientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.